Study of CB-183,315 in Participants With Clostridium Difficile Infection

NCT01085591 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Clostridium Difficile Infection
Diarrhea

Interventions

DRUG: CB-183,315
DRUG: Placebo
DRUG: Vancomycin

Sponsor

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)